Murphy SC, Deye GA, Sim BKL, Galbiati S, et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog 2021;17:e1009594.
PMID: 34048504